Jove
Visualize
联系我们

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

<i>OCT1</i> Variants Are Associated with Metformin Clearance and Gluconeogenesis: Mechanistic Insights for Youth-Onset Type 2 Diabetes in the MIGHTY Study.

medRxiv : the preprint server for health sciences·2026
Same author

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Blood advances·2026
Same author

Halofantrine protects photoreceptors in multiple models of retinal degeneration.

Research square·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jun 23, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.9K

复发性扩散性大B细胞淋巴瘤的组合向疗法

Christopher Melani1, Rahul Lakhotia1, Stefania Pittaluga1

  • 1From the Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) - all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.).

The New England journal of medicine
|June 20, 2024
PubMed
概括
此摘要是机器生成的。

ViPOR疗法在特定的扩散性大B细胞淋巴瘤 (DLBCL) 亚型中显示出持久的缓解. 这种组合疗法,包括venetoclax,在复发或耐药DLBCL患者中显示出可管理的不良事件.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

相关实验视频

Last Updated: Jun 23, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学
  • 临床药理学 临床药理学

背景情况:

  • 向扩散型大B细胞淋巴瘤 (DLBCL) 的瘤突变导致了特定途径的药物.
  • 通过针对DLBCL多重生存途径进行治愈治疗的潜力仍然是未知的.

研究的目的:

  • 评估一种新型组合治疗方案ViPOR的安全性和有效性,用于复发性或耐药性DLBCL的患者.
  • 在ViPOR疗法中确定推的2期venetoclax剂量.

主要方法:

  • 进行了一项单中心的1b-2期研究,对venetoclax,ibrutinib,prednisone,obinutuzumab和lenalidomide (ViPOR) 进行了研究.
  • 第1b阶段确定了venetoclax (800毫克) 的推剂量,第二阶段评估了DLBCL患者的疗效.
  • 维波尔每21天进行一次,持续6个周期.

主要成果:

  • 3级内出血的剂量限制性毒性确定了venetoclax的第二阶段剂量.
  • 在48名可评估的DLBCL患者中,客观反应为54%,完全反应为38%.
  • 在非GCB DLBCL和具有特定基因重组的高度B细胞淋巴瘤中观察到完全反应;无进展的2年生存率为34%,总生存率为36%.

结论:

  • 在具有特定分子DLBCL亚型的患者中,ViPOR疗法实现了持久的缓解.
  • 与ViPOR相关的不良事件主要是可逆的.
  • 这项研究由国家癌症研究所和其他机构 (ClinicalTrials.gov NCT03223610) 资助.